NewAmsterdam Pharma Company N.V. Warrant 2022-22.11.2027 on NewAmsterdam Pharma
No trades
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.61 USD
−241.60 M USD
45.56 M USD
74.54 M
About NewAmsterdam Pharma Company N.V.
Sector
Industry
CEO
Michael H. Davidson
Website
Headquarters
Naarden
Founded
2022
ISIN
NL00150012K9
FIGI
BBG01BNP2MK0
NewAmsterdam Pharma Co. NV is a clinical-stage biopharmaceutical company, which engages in the development of oral, non-statin medicine for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol. Its lead product candidate, Obicetrapib, is a next-generation, oral, low-dose cholesteryl ester transfer protein inhibitor, which will be used to prevent major adverse cardiovascular events. The company was founded on June 10, 2022 and is headquartered in Naarden, the Netherlands.
Displays a symbol's price movements over previous years to identify recurring trends.